Price
No data yet.
Social Signal Score
Analyst Ratings
21 analystsRevenue
$2.96MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joseph E. Payne
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 109
- Beta
- 2.48
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 0.49
Financials
Revenue
$2.96M-23.0%Net Income
$-23.79MEBITDA
$-23.79MFree Cash Flow
$-19.91MEPS (diluted)
$-0.84Shares Outstanding (diluted)
28.42M+621.8%Operating Expenses
$28.50MCash & Debt
$191.48MReturn of Capital
$0.00Revenue by Segment (annual)
$82.03MDividend per Share
$0.06Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $67.22M | $-65.78M | $-2.40 |
| 2024 | $138.39M | $-80.94M | $-3.00 |
| 2023 | $157.75M | $-29.73M | $-1.12 |
| 2022 | $205.75M | $9.35M | $0.35 |
| 2021 | $12.36M | $-203.67M | $-7.74 |
| 2020 | $9.54M | $-72.15M | $-3.55 |
| 2019 | $20.79M | $-25.99M | $-2.13 |
| 2018 | $15.75M | $-21.79M | $-2.16 |
| 2017 | $13.00M | $-10.90M | $-3.53 |
| 2016 | $20.38M | $-24.60M | $-6.25 |
| 2015 | $6.14M | $-19.45M | $-6.29 |
| 2014 | $0.00 | $-32.83M | $-16.81 |
| 2013 | $0.00 | $-10.55M | $-7.25 |
| 2012 | $0.00 | $-1.58M | $-0.99 |
Valuation
ARCThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
160+220.00%Social Signal Score
Mentions (6)
- Newsmarketbeat.com·11d ago·Neutral
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform Arcturus Therapeutics NASDAQ: ARCT presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to introduce a next-generation delivery platform into the program.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript
View source ↗ - Newsseekingalpha.com·14d ago·Negative
Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program Arcturus Therapeutics is advancing mRNA-based therapies, with ARCT-810 for OTC deficiency as a near-term catalyst and ARCT-032 for cystic fibrosis in phase 2. ARCT-810 has shown promising phase 2 interim data, normalizing glutamine and ammonia levels, and is designated Orphan Drug, Fast Track, and Rare Pediatric Disease by the FDA. The upcoming Sep. 23 presentation on ARCT-810 could be stock-moving, but small trial sizes m…
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newszacks.com·39d ago·Positive
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy? After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a good stock pick from a technical perspective. ARCT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Canaccord discussion.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.67 per share
Typical surprise +15.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.84 vs $-1.00beat
- Thu, May 7$-0.95 vs $-1.03beat
- Tue, Mar 3$-1.03 vs $-0.92miss
- Mon, Nov 10$-0.49 vs $-0.80beat
- Mon, Aug 11$-0.34 vs $-0.89beat
- Mon, May 12$-0.52 vs $-1.58beat
Estimates and results for ARCT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARCT officers and directors.
- Bought
- $41k
- Sold
- $6.6m
2 trades
17 trades
- Sassine Andybought
- Sassine Andybought
- Chivukula Padsold
- Sassine Andysold
- Chivukula Padsold
- Chivukula Padsold
- Chivukula Padsold
- Chivukula Padsold
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ARCT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.